Anhui Anke BioTech Group (300009) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anhui Anke BioTech Group (300009) has a cash flow conversion efficiency ratio of 0.055x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥240.51 Million ≈ $35.19 Million USD) by net assets (CN¥4.34 Billion ≈ $635.81 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300009 equity to assets ratio to measure how much of total assets are equity-financed.
Anhui Anke BioTech Group - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Anhui Anke BioTech Group's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Anhui Anke BioTech Group (300009) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Anhui Anke BioTech Group Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anhui Anke BioTech Group ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ningxia Jiaze Renewables Corp
SHG:601619
|
0.189x |
|
Far Eastern International Bank
TW:2845
|
-0.049x |
|
Western Union Co
NYSE:WU
|
0.120x |
|
Entra ASA
OL:ENTRA
|
0.054x |
|
VusionGroup
PA:VU
|
1.509x |
|
STROEER (UNSP.ARD)/4/1
F:SAXB
|
0.231x |
|
Gansu Jingyuan Coal Industry and Electricity Power Co Ltd
SHE:000552
|
0.029x |
|
Batu Kawan Bhd
KLSE:1899
|
-0.060x |
Annual Cash Flow Conversion Efficiency for Anhui Anke BioTech Group (2006–2024)
The table below shows the annual cash flow conversion efficiency of Anhui Anke BioTech Group from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Anhui Anke BioTech Group market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥4.30 Billion ≈ $629.22 Million |
CN¥685.37 Million ≈ $100.29 Million |
0.159x | -36.37% |
| 2023-12-31 | CN¥3.93 Billion ≈ $575.42 Million |
CN¥985.01 Million ≈ $144.14 Million |
0.250x | +21.91% |
| 2022-12-31 | CN¥3.40 Billion ≈ $497.78 Million |
CN¥698.98 Million ≈ $102.28 Million |
0.205x | +0.75% |
| 2021-12-31 | CN¥2.90 Billion ≈ $424.88 Million |
CN¥592.17 Million ≈ $86.65 Million |
0.204x | +28.50% |
| 2020-12-31 | CN¥2.93 Billion ≈ $428.54 Million |
CN¥464.80 Million ≈ $68.01 Million |
0.159x | +44.95% |
| 2019-12-31 | CN¥2.70 Billion ≈ $395.10 Million |
CN¥295.63 Million ≈ $43.26 Million |
0.109x | -23.41% |
| 2018-12-31 | CN¥2.01 Billion ≈ $294.29 Million |
CN¥287.49 Million ≈ $42.07 Million |
0.143x | -10.32% |
| 2017-12-31 | CN¥1.76 Billion ≈ $257.60 Million |
CN¥280.63 Million ≈ $41.06 Million |
0.159x | -11.88% |
| 2016-12-31 | CN¥1.43 Billion ≈ $208.70 Million |
CN¥258.01 Million ≈ $37.75 Million |
0.181x | +92.66% |
| 2015-12-31 | CN¥1.26 Billion ≈ $185.03 Million |
CN¥118.73 Million ≈ $17.37 Million |
0.094x | -33.17% |
| 2014-12-31 | CN¥773.47 Million ≈ $113.18 Million |
CN¥108.68 Million ≈ $15.90 Million |
0.141x | +74.44% |
| 2013-12-31 | CN¥660.60 Million ≈ $96.67 Million |
CN¥53.21 Million ≈ $7.79 Million |
0.081x | -13.16% |
| 2012-12-31 | CN¥580.03 Million ≈ $84.88 Million |
CN¥53.80 Million ≈ $7.87 Million |
0.093x | +602.56% |
| 2011-12-31 | CN¥543.88 Million ≈ $79.59 Million |
CN¥7.18 Million ≈ $1.05 Million |
0.013x | -85.46% |
| 2010-12-31 | CN¥522.30 Million ≈ $76.43 Million |
CN¥47.43 Million ≈ $6.94 Million |
0.091x | +16.32% |
| 2009-12-31 | CN¥495.41 Million ≈ $72.49 Million |
CN¥38.67 Million ≈ $5.66 Million |
0.078x | -55.44% |
| 2008-12-31 | CN¥148.64 Million ≈ $21.75 Million |
CN¥26.04 Million ≈ $3.81 Million |
0.175x | -31.56% |
| 2007-12-31 | CN¥137.09 Million ≈ $20.06 Million |
CN¥35.10 Million ≈ $5.14 Million |
0.256x | +5.30% |
| 2006-12-31 | CN¥122.00 Million ≈ $17.85 Million |
CN¥29.66 Million ≈ $4.34 Million |
0.243x | -- |
About Anhui Anke BioTech Group
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterf… Read more